Active Ingredient History

  • Now
Brivaracetam (UCB 34714, trade name Briviact), the 4-n-propyl analog of levetiracetam, is a racetam derivative with anticonvulsant properties. Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy. Brivaracetam is believed to act by binding to the ubiquitous synaptic vesicle glycoprotein 2A (SV2A), like levetiracetam, but with 20-fold greater affinity. There is some evidence that racetams including levetiracetam and brivaracetam access the luminal side of recycling synaptic vesicles during vesicular endocytosis. They may reduce excitatory neurotransmitter release and enhance synaptic depression during trains of high-frequency activity, such as is believed to occur during epileptic activity.   NCATS

  • SMILES: CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
  • Mol. Mass: 212.2887
  • ALogP: 0.9
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral, Parenteral
  • Pro Drug: No

Drug Pricing (per unit)


$2.0658 - $144.5935

United States

$2.8138 - $24.9970
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphas,4r)- | 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide | (2s)-2-((4r)-2-oxo-4-propylpyrrolidin-1-yl)butanamide | brivaracetam | briviact | ucb34714 | ucb 34714 | ucb-34714


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue